Emergent Biosolutions Inc. $EBS Stock: Prescott Group Capital Management L.L.C. Grows Position

Prescott Group Capital Management L.L.C. lifted its position in Emergent Biosolutions Inc. (NYSE:EBS) by 48.0% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,143,481 shares of the biopharmaceutical company’s stock after acquiring an additional 370,710 shares during the period. Prescott Group Capital Management L.L.C. owned 2.23% of Emergent Biosolutions worth $7,547,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors have also recently made changes to their positions in EBS. BlackRock Inc. acquired a new position in Emergent Biosolutions in the 2nd quarter valued at $39,525,000. Dimensional Fund Advisors LP boosted its stake in Emergent Biosolutions by 22.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 2,757,158 shares of the biopharmaceutical company’s stock worth $22,884,000 after purchasing an additional 504,553 shares during the last quarter. Ancora Advisors LLC acquired a new stake in Emergent Biosolutions during the 2nd quarter worth $8,949,000. Renaissance Technologies LLC grew its holdings in shares of Emergent Biosolutions by 13.7% during the first quarter. Renaissance Technologies LLC now owns 656,047 shares of the biopharmaceutical company’s stock worth $5,445,000 after buying an additional 78,900 shares in the last quarter. Finally, Palisade Capital Management LP purchased a new stake in shares of Emergent Biosolutions during the second quarter worth $4,316,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Weiss Ratings upgraded shares of Emergent Biosolutions from a “sell (d-)” rating to a “sell (d)” rating in a research report on Friday, August 21st. Zacks Research upgraded shares of Emergent Biosolutions to a “hold” rating in a research report on Tuesday, August 11th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Emergent Biosolutions in a research note on Wednesday, September 9th. Finally, JPMorgan Chase & Co. initiated coverage on shares of Emergent Biosolutions in a report on Friday, August 21st. They issued an “underweight” rating for the company. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Emergent Biosolutions has a consensus rating of “Hold” and an average price target of $10.00.

Emergent Biosolutions Price Performance

Shares of EBS opened at $6.24 on Wednesday. Emergent Biosolutions Inc. has a 52-week low of $4.36 and a 52-week high of $14.06. The stock has a fifty day simple moving average of $6.52 and a two-hundred day simple moving average of $7.99. The company has a quick ratio of 2.95, a current ratio of 5.42 and a debt-to-equity ratio of 1.70.

Emergent Biosolutions (NYSE:EBS) last announced its quarterly earnings results on Monday, November 2nd. The biopharmaceutical company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.39) by $0.03. The firm had revenue of $110.00 million for the quarter, compared to analysts’ expectations of $123.22 million. Emergent Biosolutions had a negative net margin of 40.16% and a negative return on equity of 0.40%. Analysts predict that Emergent Biosolutions Inc. will post 0.13 EPS for the current year.

Emergent Biosolutions News Roundup

Here are the key news stories impacting Emergent Biosolutions this week:

• Positive Sentiment: Third-quarter adjusted loss per share was $0.36, narrower than the $0.39 loss analysts expected. The company also said quarterly revenue of $110 million was in line with its own guidance. Earnings report
• Positive Sentiment: Restructuring actions are expected to produce $40 million in annualized savings, which could support profitability as the company continues its transformation. Long-term investor takeaways
• Neutral Sentiment: Trading in EBS was temporarily halted for an LULD pause. The notice gives no specific catalyst or directional signal, but indicates a period of elevated price volatility.
• Negative Sentiment: Emergent cut its FY 2026 revenue outlook to $600 million–$645 million, below the $656.2 million consensus estimate. Coverage characterized this as a second consecutive cut to revenue and EBITDA guidance, raising concerns about the company’s near-term growth and execution. Guidance coverage
• Negative Sentiment: Despite the adjusted EPS beat, quarterly revenue of $110 million fell short of analysts’ $123.22 million estimate, tempering the earnings surprise. Third-quarter results

Insider Transactions at Emergent Biosolutions

In other Emergent Biosolutions news, Director Donald Degolyer sold 17,800 shares of Emergent Biosolutions stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $7.09, for a total transaction of $126,202.00. Following the transaction, the director directly owned 111,921 shares of the company’s stock, valued at $793,519.89. The trade was a 13.72% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.00% of the company’s stock.

About Emergent Biosolutions

Emergent BioSolutions Inc is a life sciences company that develops, manufactures and supplies medical countermeasures for public health threats. Its portfolio has included products for protection against anthrax and smallpox, as well as treatments and emergency medicines used in overdose response and other acute-care settings.

The company has also provided contract development and manufacturing services for pharmaceutical and biotechnology companies, supporting activities such as drug substance and product manufacturing, packaging and related commercialization services.